Ładuje się......
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Tumour hypoxia has been pursued as a cancer drug target for over 30 years, most notably using bioreductive (hypoxia-activated) prodrugs that target antineoplastic agents to low-oxygen tumour compartments. Despite compelling evidence linking hypoxia with treatment resistance and adverse prognosis, a...
Zapisane w:
| Wydane w: | Br J Cancer |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Publishing Group
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865974/ https://ncbi.nlm.nih.gov/pubmed/27070712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.79 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|